HMOX1 and Hyperbilirubinemia: However, blocking of HO-activity has therapeutically been used in preterm infants since administration of SnMP, a competitive inhibitor of HO-1 and HO-2, attenuates the development of hyperbilirubinemia (Valaes et al., 1994).